Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instituto Rosenbusch's earnings per share without non-recurring items for the
three
months ended in Dec. 2025 was ARS-31.78.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was ARS-107.95.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -467.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Instituto Rosenbusch's EPS without NRI or its related term are showing as below:
BUE:ROSE'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -467.1 Med: -62.8 Max: 87.9
Current: -467.1
During the past 13 years, Instituto Rosenbusch's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 87.90% per year. The lowest was -467.10% per year. And the median was -62.80% per year.
BUE:ROSE's 3-Year EPS without NRI Growth Rate is ranked worse than 99.87% of 788
companies
in the Drug Manufacturers industry
Industry Median: 9.65
vs BUE:ROSE: -467.10
Instituto Rosenbusch's EPS (Basic) for the
three
months ended in Dec. 2025 was ARS-31.78.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was ARS-107.95.
Instituto Rosenbusch (BUE:ROSE) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Instituto Rosenbusch EPS without NRI Related Terms
Instituto Rosenbusch EPS without NRI Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-107.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a EPS without NRI of ARS-107.95 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Instituto Rosenbusch and its competitors. According to the industry distribution chart, Instituto Rosenbusch ranks #787 out of 788 companies in the Drug Manufacturers industry, placing it in the top 99.9%.
Is Instituto Rosenbusch's EPS without NRI too high?
Instituto Rosenbusch's current EPS without NRI is ARS-107.95. Based on the distribution chart, Instituto Rosenbusch ranks #787 out of 788 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #787 out of 788 companies for EPS without NRI. This places Instituto Rosenbusch in the lower half of its industry. The industry median EPS without NRI is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.65, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current EPS without NRI is ARS-107.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.25, compared to a current price of ARS158.50 — trading 154.6% above its estimated fair value. The current EPS without NRI is ARS-107.95. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current EPS without NRI is ARS-107.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS158.50 is trading 154.6% above its estimated GF Value™ of ARS62.25.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
EPS without NRI: ARS-107.95
GF Value™: ARS62.25 vs. price of ARS158.50 (154.6% above fair value)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score
Get the complete analysis for BUE:ROSE
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
